A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC

Official Title

A Phase IB, Open-Label, Multi-Centre Study to Determine the Efficacy and Safety of Durvalumab and/or Novel Oncology Therapies, With or Without Chemotherapy, for First-Line Stage IV Non-Small Cell Lung Cancer (NSCLC) (MAGELLAN)

Summary:

This study is designed to determine the efficacy and safety of durvalumab and/or novel oncology therapies, with or without chemotherapy, for first-line Stage IV Non-Small Cell Lung Cancer (NSCLC)

Trial Description

Primary Outcome:

  • Assessment of AEs by CTCAE v5.0
Secondary Outcome:
  • Objective Response Rate (ORR)
  • Duration of Response (DoR)
  • Progression Free Survival (PFS)
  • Overall Survival (OS)
  • Blood concentration of durvalumab and novel oncology therapies
  • Frequency of anti-drug antibodies (ADAs) for durvalumab and applicable novel oncology therapies
This is a Phase IB, Open-Label, Multi-Centre Study to Determine the Efficacy and Safety of Durvalumab and/or Novel Oncology Therapies, With or Without Chemotherapy, for First-Line Stage IV Non-Small Cell Lung Cancer (NSCLC).

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society